Endocyte, Inc.(NASDAQ : ECYT)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-2.15%||152.86||0.7%||$1193.05m|
|MRK||Merck & Co., Inc.||-1.56%||72.16||0.7%||$851.01m|
|BMY||Bristol-Myers Squibb Co.||-2.03%||59.52||1.0%||$795.69m|
|LLY||Eli Lilly & Co.||-0.78%||200.42||1.1%||$642.23m|
|NVO||Novo Nordisk A/S||-2.98%||69.33||0.1%||$84.61m|
|KALV||KalVista Pharmaceuticals, Inc.||-3.60%||31.03||0.4%||$80.73m|
|RPRX||Royalty Pharma Plc||-3.70%||41.96||0.2%||$79.81m|
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.